Clinical trials
Solid Tumor clinical trials
Below are recruiting solid tumor clinical trials, each written for real people, not researchers. We’re tracking 1,689 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06760819RecruitingPhase 2
Sevacertinib for solid tumors with HER2 mutations
This study tests an oral tablet called sevacertinib in people with solid tumors (not lung cancer) that have a HER2 mutation. It aims to see how well the drug works and how safe it is for people who have tried other treatments or have no good options left.
Birmingham, AlabamaAges 18 years+ - NCT07415031RecruitingPhase 2
Long term treatment with adagrasib for solid tumor patients
This trial allows people with solid tumors who are already benefiting from the study drug adagrasib in an earlier Mirati study to continue getting it for the long term. It’s for people whose doctors see ongoing benefit and who still meet the safety rules.
Phoenix, ArizonaAges 18 years+ - NCT05146440RecruitingPhase 1/Phase 2
Test drug PM14 alone and with radiation for soft-tissue sarcoma
This early-phase study tests PM14 (a new cancer treatment) to see if it can shrink tumors in soft-tissue sarcoma. Some people also receive radiation, aiming to improve tumor control while keeping side effects manageable.
Zaragoza, AragonAges 18–75 - NCT04945330Recruiting
Study for NTRK fusion cancers taking larotrectinib
This trial is for people with advanced or returning solid tumors that have specific gene changes called NTRK gene fusions. It looks at patients who are already being treated with larotrectinib as part of normal care, to understand this treatment in real life.
Multiple LocationsAges Any age - NCT06069570RecruitingPhase 1
Gamma delta T cells and low dose radiation for advanced lung or bone cancer
This trial tests a new type of immune cell called gamma delta T cells combined with low-dose radiation to treat people with advanced lung cancer or solid tumors that have spread to the bone. It is only for patients who have already tried standard treatments and either didn't get better or couldn't tolerate them.
Tucson, ArizonaAges 18 years+ - NCT06218914RecruitingPhase 1
Study of a new treatment for KRAS G12D cancers
This trial tests a new type of cell therapy (called TCR-T) that targets a specific genetic change (KRAS G12D) in advanced solid tumors that have stopped responding to standard treatments. It may be an option if your cancer has this mutation and you have a specific tissue type (HLA).
Duarte, CaliforniaAges 18 years+ - NCT06228326RecruitingPhase 1/Phase 2
Study of KB707 for advanced cancers affecting the lungs
This trial tests a new medicine called KB707 for people with advanced cancers that affect the lungs. It uses a virus to deliver a gene that may help your immune system fight the tumor. The study is especially looking at people with lung cancer (NSCLC) or other solid tumors that have spread to the lungs and haven't responded to standard treatments.
Dothan, AlabamaAges 18 years+ - NCT07202364RecruitingPhase 2
Study of YL202 for advanced solid tumors
This trial tests a new drug called YL202 for people with advanced solid tumors (like lung, colon, or cervical cancer) who have already tried 1-2 standard treatments. It aims to see if YL202 can shrink tumors or slow their growth.
Changsha, HunanAges 18 years+ - NCT07186842RecruitingPhase 1/Phase 2
Testing the safety of BNT329 for advanced CA19-9 positive tumors
This trial tests if the investigational drug BNT329 is safe and could help people with advanced solid tumors that make a marker called CA19-9. It is for those who have tried standard treatments and need new options.
Denver, ColoradoAges 18 years+ - NCT05176483RecruitingPhase 1
New drug combinations for advanced solid tumors
This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.
Phoenix, ArizonaAges 18 years+ - NCT03947385RecruitingPhase 1/Phase 2
First drug test for metastatic uveal melanoma with specific gene changes
This Phase 1/2 trial studies IDE196 in adults with metastatic uveal melanoma that has certain gene mutations or fusions. It’s mainly testing safety and correct dosing, and may help shrink tumors in patients matched to the tumor’s genetic changes.
Los Angeles, CaliforniaAges 18 years+ - NCT04970121RecruitingPhase 2
Duloxetine for chemotherapy nerve pain in solid tumor patients
This Phase 2 trial tests duloxetine to see if it safely reduces painful nerve damage caused by chemotherapy (especially taxanes) in people with solid tumors. If you have moderate-to-severe nerve pain and meet lab and heart-safety checks, this study may be an option.
Bengbu, AnhuiAges 18–75 - NCT04981119Recruiting
Test apheresis for CAR T manufacturing in HLA-A2 solid tumors
This trial studies how a process called apheresis is used to make CAR T cells for people with certain solid tumors. It is designed for tumors that have lost a specific immune marker (HLA-A*02), which may affect how well CAR T therapies work.
Gilbert, ArizonaAges 18 years+ - NCT04683250RecruitingPhase 1/Phase 2
RET-targeting drug study for advanced cancers with RET changes
This trial tests an “RET-inhibitor” medicine (TAS0953/HM06) for advanced solid tumors that have RET gene changes. It may help shrink tumors by blocking cancer growth signals from the RET gene.
Orange, CaliforniaAges 18 years+ - NCT05761314Recruiting
Study treatments for cancers in people with RASopathy
This study looks at people who have a RASopathy—a genetic condition—and also have solid tumors (tumor growths not in blood). To join, your RASopathy must be confirmed by genetic testing, not only by symptoms.
RomaAges Any age - NCT06040541RecruitingPhase 1
Study of RMC-9805 for KRAS G12D solid tumors
This trial tests an experimental pill (RMC-9805) for people with solid tumors that have a specific KRAS G12D mutation. It's for those who have already tried other treatments and need new options.
Sacramento, CaliforniaAges 18 years+ - NCT06326411RecruitingPhase 1
Testing NST-628 pills for advanced solid tumors with RAS/MAPK changes
This trial tests an experimental pill called NST-628 for people with advanced solid tumors that have specific genetic changes in the RAS/MAPK pathway. The goal is to see if it is safe and effective when other treatments are no longer working.
San Francisco, CaliforniaAges 18 years+ - NCT04928677RecruitingPhase 1
Codrituzumab for children and young adults with GPC3-positive solid tumors
This Phase 1 study tests codrituzumab, an antibody medicine, in children and young adults whose solid tumor has come back or did not respond to standard treatment. It’s designed to see how the treatment works and how safe it is, especially for tumors that test positive for GPC3.
Los Angeles, CaliforniaAges 1–21 - NCT06789172RecruitingPhase 1
New drug OKN4395 with or without pembrolizumab for solid tumors
This trial tests a new oral drug called OKN4395, which targets a COX2-related immune pathway, alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors. It may be an option if you have certain types of cancer that have stopped responding to other treatments.
Beverly Hills, CaliforniaAges 18 years+ - NCT07036133RecruitingPhase 1
Study of Pralatrexate in patients with advanced cancer and liver problems
This trial tests a drug called pralatrexate in people with advanced solid tumors or blood cancers, including those with different levels of liver function. The goal is to understand how the drug works in the body and how safe it is for patients with various degrees of liver impairment.
Cerritos, CaliforniaAges 18 years+ - NCT06712680RecruitingPhase 1/Phase 2
Study of HYP-6589 for advanced solid tumors
This trial tests a new drug, HYP-6589, alone for advanced solid tumors or combined with targeted therapy for advanced non-small cell lung cancer with specific gene changes. It aims to see if the treatment is safe and effective, and may help people whose cancer has spread or cannot be removed with surgery.
Guangzhou, GuangdongAges 18–80 - NCT07021534RecruitingPhase 1
CAR-NK and CAR-T cells for cancer with liver spread
This trial tests a new treatment that uses special immune cells (CAR-NK and CAR-T cells) given directly into the liver artery, then through a vein, to fight advanced solid tumors that have spread to the liver. It is for people who have already tried standard treatments and need new options.
Hangzhou, ZhejiangAges 18–75 - NCT05538130RecruitingPhase 1
Study medicine for BRAF-mutated advanced solid tumors
This Phase 1 trial studies how PF-07799544 works and what dose is safest in people with advanced cancer that has a specific genetic change called BRAF V600. You may receive it alone or with another treatment, depending on the tumor group, to see if it can treat the cancer.
Birmingham, AlabamaAges 16 years+ - NCT06774963RecruitingPhase 1
Study of LNCB74 for advanced solid tumors
This trial tests a new drug called LNCB74 for people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and effective.
Newport Beach, CaliforniaAges 18 years+
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for solid tumor?
- Yes. Clin2 currently lists 1,689 recruiting solid tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a solid tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a solid tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.